Hypertrophic Cardiomyopathy: EP Considerations-Atrial Fibrillation: Treatment Options and Outcomes (Presenter: Ethan J Rowin,)

Atrial Fibrillation: Treatment Options and Outcomes (Presenter: Ethan J Rowin,)

Video Transcription

Video Summary

Atrial fibrillation (AFib) is a common complication in hypertrophic cardiomyopathy (HCM), occurring in about 20% of patients. It is the most common sustained arrhythmia in HCM and is four times more common than ventricular arrhythmias that may lead to sudden death. AFib prevalence increases with age but can also occur in younger HCM patients. In the past, AFib was considered a major determinant of HCM-related mortality, but with advancements in treatment, its prognosis has changed. Aggressive rhythm control using antiarrhythmic medications or ablation procedures has been effective in managing AFib. Anticoagulation is recommended for all HCM patients after their first episode of symptomatic AFib. With treatment, the natural history of AFib in HCM is not inevitably progressive and disease-related mortality is low. However, there is limited data on the management of asymptomatic AFib.

Meta Tag

Lecture ID 3795

Location Room 152

Presenter Ethan J Rowin,

Role Invited Speaker

Session Date and Time May 09, 2019 10:30 AM - 12:00 PM

Session Number S-012

Keywords

Atrial fibrillation

Hypertrophic cardiomyopathy

Arrhythmia

Rhythm control

Anticoagulation